Clinical trials: Cancer (Solid Tumors)
Cancer
Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy
YH004 is a humanized monoclonal antibody that specifically binds to 4-1BB, and acts as an agonist against 4-1BB. This first in human study of YH004 is designed to establish the maximum tolerated dose (MTD) and/or the recommended…
- Trial name
- NCT05040932
- Testing
- YH004
- Where
- 3 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
SARS-CoV-2 Infection
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
If a treated cancer patient cannot make antibodies to a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Emergency Use Authorization (EUA) or approved vaccine, their risk for infection and its sequelae are…
- Trial name
- NCT05438498
- Testing
- Evusheld (tixagevimab+cilgavimab) IM or IV
- Where
- 40 sites in United States
- Volunteers
- 550 people
- Sponsor
- MediMergent, LLC
Solid Tumor, Renal Cell Carcinoma (Kidney Cancer)
A Study of NDI 1150-101 in Patients With Solid Tumors
This study is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) and to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of NDI-101150 given as…
- Conditions
- Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05128487
- Testing
- NDI-101150, Pembrolizumab
- Where
- 19 sites in United States
- Volunteers
- 106 people
- Sponsor
- Nimbus Saturn, Inc.
Solid Tumors, Sarcomas
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.
- Trial name
- NCT07374848
- Testing
- ZL-6201
- Where
- 8 sites in United States, China
- Volunteers
- 180 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Advanced Cancer, Gastric Cancer
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
This is an open label Phase I/IIa, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody as monotherapy or in combination with nivolumab or standard of care.
- Conditions
- Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
- Trial name
- NCT04396821
- Testing
- TST001, Nivolumab Injection [Opdivo], mFOLFOX6
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Neoplasm Malignant
Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients
Primary Objective: In the dose escalation: to determine the maximum tolerated dose (MTD) of SAR125844. In the expansion cohort: to evaluate the preliminary anti-tumoral effect of SAR125844 in patients with measurable and MET gene…
- Trial name
- SARMETA (NCT01657214)
- Testing
- SAR125844
- Where
- 8 sites in Japan, South Korea
- Volunteers
- 70 people
- Sponsor
- Sanofi
Advanced Solid Tumors
ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
This is a Phase 1b, multicenter, single arm, open label, dose escalation study to determine the MTD and evaluate the safety and preliminary antitumor activity of orally (PO) administered ACY 241 in combination with intravenously…
- Trial name
- NCT02551185
- Testing
- ACY-241
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Celgene
Solid Tumor, Adult
Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors
The main purpose of this first-in-human study of GEN1056, is to evaluate safety. In addition, the study will determine the recommended dose and frequency for subsequent clinical studies and will assess the preliminary anti-tumor…
- Trial name
- NCT05586321
- Testing
- GEN1056
- Where
- 7 sites in Georgia, Moldova and 1 more
- Volunteers
- 26 people
- Sponsor
- Genmab
Advanced EGFR Positive Solid Tumor
ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to…
- Trial name
- NCT04412616
- Testing
- ZZ06
- Where
- 5 sites in United States, China
- Volunteers
- 60 people
- Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
Colorectal Cancer, Solid Tumors
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of revumenib in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.
- Trial name
- NCT05731947
- Testing
- Revumenib, Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- Syndax Pharmaceuticals
HER2-positive Breast Cancer, HER2-positive Gastric Cancer
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.
- Conditions
- HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Bladder Cancer, HER2-positive Solid Tumor
- Trial name
- NCT03650348
- Testing
- PRS-343 in Combination with Atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Pieris Pharmaceuticals, Inc.
Neoplasms
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GSK3359609 is an anti-Inducible T cell Co-Stimulator (ICOS) receptor agonist antibody intended for the treatment of cancers of different histology.
- Trial name
- NCT02723955
- Testing
- feladilimab (GSK3359609), GSK3174998, Pembrolizumab
- Where
- 28 sites in United States, Australia and 7 more
- Volunteers
- 829 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumor, Cancer
Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors
This is a prospective, single-center, open-label, real-world clinical study designed to evaluate the safety, efficacy, and immunogenicity of Personalized neoantigen-pulsed autologous dendritic cell Injections （ZSNeo-DC）in…
- Conditions
- Advanced Solid Tumor, Cancer, Malignant Solid Tumor
- Trial name
- ZSNeo-DC-RWS (NCT07752953)
- Testing
- Personalized neoantigen-pulsed autologous dendritic cell Injections （ZSNeo-DC）, Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 100 people
- Sponsor
- ZSky Biotech Inc
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Neoplasms, Triple-Negative Breast Cancer
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06647263 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02078752
- Testing
- PF-06647263
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
This is an Expanded Access Program (EAP) that will give the participants access to the drug SL-28 before it is approved by the FDA.
- Conditions
- Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory, Advanced Cancer, Advanced Malignant Neoplasm
- Trial name
- NCT06872489
- Testing
- SL-28.
- Sponsor
- Second Life Therapeutics
Advanced Solid Tumor
Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors
This is an open label, phase 1 clinical study to evaluate the safety, tolerability, dose limiting toxicities (DLTs), maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended phase 2 dose (RP2D) of QLS31904…
- Trial name
- NCT05461287
- Testing
- QLS31904
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Breast Neoplasms, Lung Neoplasms
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
DiaTech is a private company performing patient specific cancer chemosensitivity testing for patients and physicians. DiaTech Oncology is doing this clinical study to see if an experimental new technology called the microculture…
- Conditions
- Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma, Soft Tissue
- Trial name
- NCT00243685
- Testing
- Laboratory Assay, Mick Assay
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Pierian Biosciences
Advanced Solid Tumor
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd antibody-drug conjugates (ADC) in participants with advanced solid tumors.
- Trial name
- NCT06244485
- Testing
- Valemetostat tosylate, T-DXd, Dato-DXd
- Where
- 35 sites in United States, China and 2 more
- Volunteers
- 210 people
- Sponsor
- Daiichi Sankyo
Squamous Cell Carcinoma of Head and Neck
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
The primary objective of this study was to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who had previously received anti-PD-(L)1 therapy but who had not achieved a CR.
- Trial name
- NCT04144517
- Testing
- Nemvaleukin Alfa, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Mural Oncology, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.